Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Effects of subacute pretreatment with carbamate together with acute adjunct pretreatment against nerve agent exposure. (Reannouncement with new availability information)

Technical Report ·
OSTI ID:91425

Acute carbamate pretreatment, in conjunction with atropine pretreatment or followed by atropine and oxime therapy has been shown to protect rabbits, rats, guinea pigs and monkeys against multiple lethal doses of soman. In those experiments, pretreated animals were usually challenged with soman at the time of peak whole blood acetylcholinesterase (AChE) inhibition by the carbamate or when the concentration of carbamate in the blood was expected to be rapidly diminishing. However, soldiers in a chemical environment, having taken carbamate orally might well be exposed to nerve agent shortly thereafter. Thus, both active carbamate and nerve agent would be entering the blood simultaneously. In a recent study it was reported that subacute administration of physostigmine (Phy), via subcutaneously implanted 28 day osmotic minipump, afforded protection against an iv challenge of soman on the 27th day.

Research Organization:
Army Medical Research Inst. of Chemical Defense, Aberdeen Proving Ground, MD (United States)
OSTI ID:
91425
Report Number(s):
AD-A--239102/7/XAB; USAMRICD-P--89-027
Country of Publication:
United States
Language:
English